Tumor angiogenesis

Journal of the Medical Association of Thailand

Volumn 82, Issue 4, 1999, Pages 393-403

  Voravud, Narin ^b   Charuruk, Navapun ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b NONE

Author keywords

Factors; Mechanism; Tumor angiogenesis

Indexed keywords

EID: 0043207894     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Liotta L, Kleinerman J, Saldel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997-1004.
3. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349(suppl 11): 13-5.
4. Folkman J, Cole P, Zimmerman S. Tumor behavior in solated perfused organs: In vivo growth and metastais of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966; 164: 491-502.
5. Holmgren L, O'Relly MS, folkman J. Dormancy of Micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149.
6. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994; 344: 82-6.
7. Montesano R, Orci L, Vassali P. In vitro rapid organization of endothellal cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983; 97: 1648-52.
8. Brem S, Brem H, Folkman J. Finkelstein D. Patz A. Prolonged tumor dormancy by prevention of neovascularization the vitreous. Cancer Res 1976; 36: 2807-12.
9. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. JNCL 1972; 48: 347-56.
10. Jain RK. Determinants of tumor blood flow. Cancer Res 1988: 2641-58.
11. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin depostition. Biochim Biophys Acta 1989; 948 305-26.
12. Folkman J. Tumor angiogenesis. In: Holland JF, Frei EF, Bast RC, Kufe DW, et al. Cancer Medicine 3rd ed. Philadelphia, Lea & Febiger. 1993: 153-70.
13. Mignatti P, Fifkin DB. Biology and biochemistry of proteinases in tumor invastion. Physiol Rev 1993; 73: 161-95.
14. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
15. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini P J. Angiogenesis mediated by soulble forms of E-Selection and vascular cell adhesion molecule-1 Matire 1995; 376: 517-9.
16. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αVβ3 for angiogenesis. Science 1994; 264: 569-71.
17. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathway be distinct αV integrins. Science 1995; 270: 1500-2.
18. Schweigerer L, Neufeld G, Friedman J, et al. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987; 325: 257-9.
19. motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene express in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990; 87: 3092-6.
20. Podor TJ, Jink Fr, Loskutoff DJ, Carlson DA, Lotzm. Human endothelial cell produce IL-6 lack response to exogenous IL-6. Ann Ny Acad Sci 1989; 557: 374-85.
21. Zsebo KM, Yuschen koff VN, Schiffer S, et al. Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-DSF. Blood 1988; 71: 99-103.
22. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
23. Mukhopadkyay D, Tsiokar L, Sukhatme VP. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth-factor gene-expression Cancer Res 1995; 55: 6161-5.
24. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinol 1993; 133: 1292-9.
25. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Path 1985; 120: 327-32.
26. Gupta SK, Hassel T, Singh JA. A potent inhibitor of endothelial cell proliferation is generated by proteolytic clavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995; 92: 7799-803.
27. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophage and angiogenesis. J Leuko Biol 1994; 55: 410-22.
28. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635-42.
29. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79: 319-6.
30. Wohlwend A, Belin D, Vassalli JD. Plasminogen activator-specific inhibitors produced by human monocyfes/macrophages. J Exp Med 1987; 165: 320-39.
31. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells:regulation of plasminogen activator activity. J Cell Biol 1992; 118: 901-9.
32. Pepper MS, Montesano R, Orci L, Vassalli JD. Plasminogen activator inhibitor-1 is induced in microvascular endothelial cells by a chondrocyte-derived transforming growth factor-beta. Biochem Biophys Res Commun 1991; 176: 633-8.
33. Sheid B. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 1992; 62: 153-8.
34. Baird A, Mormede P, Bohlen P. Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggests its indentity with macrophage-derived growth factor. Biochem Biophys Res Commun 1985; 126: 385-64.
35. Rappolec D A, Mark D, Banda MJ, Weerb Z. Wound macrophages express TGF-alpha and other growth factor in vivo:analysis by m RNA phenotyping. Science 1988; 241: 708-12.
36. Stracke ML, Liotta LA. Multi-step cascade of tumor cell metastasis In Vivo 1992; 6: 306-16.
37. Weinstat-Saslow D, Steeg Ps. Angiogenesis and colonization in tumor metastatic process:basic and applied advances. FASEB 1994; 8: 401-7.
38. Ballin M, Gomez D, Sinha C, Thorgeirsson U. Ras oncogene mediated induction of a 92 kDa metalloproteinase;strong correlation with the malignant phenotype. Biochem Biophys Res Commun 1988; 154: 832-8.
39. Iwasaka C, Tanaka K, Abe M, Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vaswlar endothelial cell. J Cell Physiology 1996; 169: 522-31.
40. Fox P. Sa G, Dobrowoski S, Stacey C. The regulation of endothelial cell motility by p21 ras. Oncogene 1994; 9: 3519-6.
41. Rastinejad F, Polverini PJ, Bouck NP. Regulatin of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56: 345-55.
42. Dameron KM, Volpert OV, Tainsky MA, Bouck N. The p53 tumor suppressor gene ingibits angiogenesis by stimulating the productin of thrombospondin. Cold Spring Habor Symp Quant Biol LIX 1994: 483-9.
43. Hsu S, Volpert O, Steck P, et al. Inhibition of angiogenesi in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996; 56: 5684-91.
44. Volpert O, Cameron K, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progression to tumorigenesis. Oncogene 1997.
45. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D Reversion of deregulated expression of vascular endothelial growth factor in human renal cell carcinoma by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996; 56: 2299-301.
46. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodie, as indicator of node metastasis and survival in breast cancer. Lancet 1992; 340: 1120-4.
47. Weidner N, Folkman J, Pozza F, et al. tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-87.
48. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993; 55: 371-4.
49. Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: Correlation with metastasis in head-and-neck squamous cell carcinoma. Int J Cancer 1993; 55: 739-44.
50. Srivastava S, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic sigificance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick skin melanoma. Am J Pathol 1988; 133: 419-23.
51. Vesalainen S, Lipponen P, Talja M, alhava E, Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2M0 prostatic adenocarcinoma. Anticancer Res 1994; 14: 709-14.
52. Hollingsworth HC, Hohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995; 147: 33-41.
53. Jaeger TM, Weidner N, Chew KK, Moore DH, Kerschmann RL, Waldman FM, and lymph node metastases in invasive bladder carcinoma. J Urol 151, 348a (Abstr. 482).
54. Li VW, Folkerth RD, M Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994: 344: 82-6.
55. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer: Lancet 1992; 340: 154-6.
56. Olivarez D, Ulbright T, Deriese W, et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994; 54: 2800-2.
57. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ. Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 1994; 37: 921-6.
58. Vacca A, Ribatti D, Roncati L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-8.
59. Nanus DM, Schmitz Drager BJ, Motzer RJ. et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. JNCL 1993; 85: 1597-9.
60. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994: 344: 82-6.
61. Nguyen M, Watanabe H, Budson AE, Richie JP. Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-61.
62. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55 510-3.
63. Chaplin D, Hill S, Prise V, Tozer G, Pettit G, Dark G. Combrestatin A-4 agent that displays selective toxicity towards tumor vasculature. Eur J Cancer 1997; 33: 544 (abstract 186).